Last updated on July 2019

This is an Extension Study of the Roche P-trial to Investigate Safety and Effectiveness of a Single Ocrelizumab Dose in Participants With Multiple Sclerosis (MS)


Brief description of study

This extension study will evaluate the effectiveness and safety of ocrelizumab in multiple sclerosis (MS) participants who were previously enrolled in a F. Hoffmann-La Roche (Roche) sponsored ocrelizumab phase IIIb/IV trial (i.e. the Parent, P-trial).

Detailed Study Description

This is a single arm, open label, multicenter extension study in participants on ocrelizumab therapy at the end of Treatment period of the Roche P-trial. Participants will receive treatment with ocrelizumab as single 600 mg infusions every 24 weeks for two years.

Clinical Study Identifier: NCT03599245

Find a site near you

Start Over

Maasstadziekenhuis

Rotterdam, Netherlands
  Connect »

Zuyderland Medisch Centrum

Sittard-Geleen, Netherlands
  Connect »

Raigmore Hospital

Inverness, United Kingdom
  Connect »

Kings College Hospital

London, United Kingdom
  Connect »

St George's Hospital

London, United Kingdom
  Connect »

Charing Cross Hospital

London, United Kingdom
  Connect »

Royal Victoria Infirmary

Newcastle upon Tyne, United Kingdom
  Connect »

Royal Hallamshire Hospita

Sheffield, United Kingdom
  Connect »

Morriston Hospital

Swansea, United Kingdom
  Connect »